Zarxio and Cellulitis - a phase IV clinical study of FDA data

Summary:

Cellulitis is reported as a side effect among people who take Zarxio (filgrastim-sndz), especially for people who are female, 60+ old, also take Vitamin D, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Cellulitis when taking Zarxio. It is created by eHealthMe based on reports of 3,248 people who have side effects when taking Zarxio from the FDA, and is updated regularly.

What is Zarxio?

Zarxio has active ingredients of filgrastim-sndz. eHealthMe is studying from 3,250 Zarxio users. Check the latest studies of Zarxio.

What is Cellulitis?

Cellulitis (infection under the skin) is found to be associated with 2,084 drugs and 2,338 conditions by eHealthMe. Check the latest studies of Cellulitis.

On Jul, 19, 2026

3,248 people reported to have side effects when taking Zarxio.
Among them, 15 people (0.46%) have Cellulitis.

Among these 15 people:

What is the gender of people who have Cellulitis when taking Zarxio? *

female: 73.33 %
male: 26.67 %

What is the age of people who have Cellulitis when taking Zarxio? *

What are other drugs people take besides Zarxio? *

What are other side effects people have besides Cellulitis? *

High Blood Pressure: 5 people, 33.33%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 5 people, 33.33%
Fatigue (feeling of tiredness): 5 people, 33.33%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 5 people, 33.33%
Headache (pain in head): 5 people, 33.33%
Staphylococcal Infection (an infection with staphylococcus bacteria): 5 people, 33.33%
Malaise (a feeling of general discomfort or uneasiness): 5 people, 33.33%
Viral Infection: 5 people, 33.33%
Weight Fluctuation: 5 people, 33.33%
Localised Infection (infection at the single location): 4 people, 26.67%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 5 people, 33.33%
Immunodeficiency Common Variable: 5 people, 33.33%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 13.33%
Cytomegalovirus Infection: 1 person, 6.67%
Cystic Fibrosis (disease of the secretary glands): 1 person, 6.67%
Breast Cancer Female: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Zarxio and have Cellulitis?

- Check whether Cellulitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zarxio:

Zarxio (3,250 reports)

Cellulitis treatments and more:

Cellulitis (75,290 reports)

Browse all side effects of Zarxio:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cellulitis:

Cellulitis (2,084 drugs)

Browse all the conditions that are associated with Cellulitis:

Cellulitis (2,338 conditions)

Related publications that referenced our studies

Yaylaci S, Yilmaz EU, Guclu E, Kumsar NA, Tamer A, Karabay O, "Clozapine-Induced Febrile Neutropenia and Cellulitis", Turkish journal of emergency medicine, 2014 Mar .
Yaylaci S, Yilmaz EU, Guclu E, Kumsar NA, Tamer A, Karabay O, "Clozapine-Induced Febrile Neutropenia and Cellulitis", Turkish journal of emergency medicine, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on filgrastim-sndz (the active ingredients of Zarxio) and Zarxio (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.